NCHC Statement on the Pricing of Remdesivir
On Monday, June 29, Gilead announced the pricing of remdesivir, an anti-viral drug that treats COVID-19.
The Coalition supports protecting consumers from unaffordable drug costs. The pricing decision will exacerbate the health care affordability crisis already plaguing the country’s response to COVID-19. Fundamentally, the United States needs to develop a fair drug pricing system that does not rely on the good will of for-profit entities to restrain drug prices, as a matter of containing health care costs and preparing for the next crisis. Read the Coalition’s entire statement here.